Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins

1. A process for the preparation of a vaccine and neurotoxin associated proteins (NAPs) composition, comprising:

mixing an equimolar ratio of the vaccine and neurotoxin associated proteins (NAPs) into a mixture that is maintained at a pH of from 5.5 to 6.2,

wherein the vaccine comprises a detoxified recombinant protein(s) derived from one or more proteins associated with an infectious disease selected from the group consisting of tetanus, diphtheria, pertussis alone or in combination thereof;

wherein the neurotoxin associated proteins (NAPs) are derived from Clostridium botulinum or botulinum neurotoxin, and the NAPs become chemically or recombinantly linked or otherwise associated to the vaccine during the mixing;

maintaining the mixture at the pH in the range of from 5.5 to 6.2 using 25 mM phosphate buffer at a pH 5.8 containing 200 mM sodium chloride solution;

reacting the mixture with at least 10 mM imidazole solution at an ambient temperature for from 2 to 3 hours;

loading the mixture to a Nickel-Nitrilotriacetic acid (Ni-NTA) affinity column; and

eluting the column to get a pure vaccine and neurotoxin associated proteins (NAPs) composition.

2. The process of claim 1 , wherein the vaccine comprises a detoxified recombinant tetanus neurotoxin (DrTeNT).

3. The process of claim 1 , wherein the imidazole concentration is at least 50 mM.

4. The process of claim 1 , wherein the temperature is in the range of 20-30° C.

5. The process of claim 1 , wherein the mixture is maintained at a pH of 5.8.

6. The process of claim 1 , wherein the vaccine is a tetanus vaccine that is chemically or recombinantly linked or otherwise associated to a detoxified botulinum neurotoxin (DrBoNT) or any other vehicle, or carrier molecule.

7. The process of claim 1 , wherein the vaccine is a tetanus vaccine that is chemically or recombinantly linked or otherwise associated to a fragment of detoxified botulinum neurotoxin (DrBoNT).

8. The process of claim 1 , wherein the vaccine is a tetanus vaccine that is chemically or recombinantly linked or otherwise associated to the neurotoxin associated proteins (NAPs) of Clostridium botulinum or botulinum neurotoxin during the mixing of the equimolar ratio of the tetanus vaccine and the neurotoxin associated proteins (NAPs).

9. The process of claim 1 , wherein the vaccine is a tetanus vaccine that is chemically or recombinantly linked or otherwise associated to neurotoxin associated proteins (NAPs) of any other serotypes and subtypes B to G of Clostridium botulinum or botulinum neurotoxin during the mixing of the equimolar ratio of the tetanus vaccine and the neurotoxin associated proteins (NAPs).

10. The process of claim 9 , wherein the vaccine comprises a detoxified recombinant tetanus neurotoxin (DrTeNT) that is combined with a pertussis vaccine element as a fusion protein.

11. The process of claim 9 , wherein the vaccine comprises a detoxified recombinant tetanus neurotoxin (DrTeNT) that is combined with a vaccine elements of diphtheria and pertussis vaccine elements as a fusion protein.

12. The process of claim 9 , wherein the tetanus vaccine comprises detoxified recombinant tetanus neurotoxin (DrTeNT) formulated to be administered orally, subcutaneously or intraperitoneally, either alone or in combination with a vaccine elements of diphtheria and pertussis vaccine as a fusion protein.

13. The process of claim 9 , wherein the tetanus vaccine comprises a detoxified tetanus neurotoxin (DrTeNT), or one or more of its fragments that is conjugated covalently or non-covalently with a therapeutic drug comprising a therapeutic small molecule or a therapeutic biomolecules.